L-carnitine enhances survival in ratsL-carnitine increases survival in a murine model of severe verapamil toxicity.
In our controlled study involving 16 male rats, we explored the effects of intravenous (IV) L-carnitine on survival rates and heart function during severe verapamil toxicity.
We found that L-carnitine notably increased survival time, averaging about 140 minutes compared to just 49 minutes for the saline group.
Additionally, at 15 minutes, those treated with L-carnitine had significantly better blood pressure readings. This indicates that L-carnitine may help support heart function during critical toxicity events.
Read More
L-Carnitine protects against heart damageL-Carnitine Attenuates Cardiac Dysfunction by Ischemic Insults Through Akt Signaling Pathway.
We examined how L-carnitine (LC) protects the heart during heart attack situations. In our study involving mice, different groups received varying treatments, including LC before experiencing ischemia and reperfusion.
The findings revealed that LC significantly improved heart function after ischemia. Notably, its protective effects diminished when a specific pathway was blocked, indicating that LC's benefits are closely linked to the PI3K/Akt signaling pathway.
Additionally, LC enhanced heart cell performance even under low-oxygen conditions, supporting its potential as a heart protective agent during critical events.
Read More
Carnitine with vitamin E mitigates heart damagePROTECTIVE ROLE OF CARNITINE SYNERGIZED WITH VITAMIN E AGAINST ISOPROTERENOL INDUCED CARDIAC INFARCTION IN RATS.
We aimed to find out if carnitine, when paired with vitamin E, could protect rats from heart attacks induced by isoproterenol. Our study involved different groups of rats, some receiving only carnitine or vitamin E, while others received both. The results were promising, as those treated with both supplements showed significant improvements in heart function and reductions in harmful enzymes and inflammatory markers. However, we did not observe the same positive effects from carnitine alone.
Read More
Methyl-GBB provides lasting heart protectionDecrease in Long-Chain Acylcarnitine Tissue Content Determines the Duration of and Correlates with the Cardioprotective Effect of Methyl-GBB.
We examined how methyl-GBB, a carnitine transport inhibitor, impacts heart health following a treatment period. In our study with male Wistar rats, we found that after 28 days of methyl-GBB treatment, long-chain acylcarnitines (LCACs) in the heart dropped by 87%, which led to a significant reduction in heart tissue damage, or infarct size, by 57%. Remarkably, even two weeks after stopping the treatment, both the LCAC levels and damage remained lower. This research suggests a strong link between diminishing LCACs and lasting heart protection.
Read More
L-carnitine reduction protects heart tissueInhibition of L-carnitine biosynthesis and transport by methyl-γ-butyrobetaine decreases fatty acid oxidation and protects against myocardial infarction.
We explored whether reducing L-carnitine levels can safeguard the heart from damage during a heart attack. In our study, we tested a compound called Methyl-GBB that successfully lowered both L-carnitine and its associated fatty acids in heart tissue.
By inhibiting fatty acid oxidation, Methyl-GBB not only decreased the damage from heart attacks but also improved survival rates in rats. While we found promising results, it's essential to note that this study is preliminary, and the direct implications for human treatment remain uncertain.
Read More